New drug trial aims to shield transplant patients from dangerous virus
NCT ID NCT07368153
Summary
This study is testing the safety of an experimental drug designed to prevent complications from Epstein-Barr virus (EBV) in kidney transplant patients. It focuses on people who have never had EBV but receive a kidney from a donor who has. Participants will receive either the new drug or a placebo, in addition to their standard transplant medications, and be closely monitored for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel
Basel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.